ClinicalTrials.gg
CompletedNCT02804178Updated Mar 10, 2021Results posted

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

A Phase 2 interventional study of ATR-101 in Congenital Adrenal Hyperplasia, sponsored by Millendo Therapeutics, Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Millendo Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · United States.

Enrollment
27th of 38
10 · median 22
Started
2016
with 2 others
Phase 2
18 of 50
4 open now
Registered
22nd of 50
by date

Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, this one is the 27th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2016, is one of 18 in phase 2, and was the 22nd registered.

Adrenal Hyperplasia, Congenital

101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

10 of the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 multicenter, single-blind, multiple dose study to evaluate the safety and efficacy of orally administered ATR-101 in subjects with classic congenital adrenal hyperplasia (CAH). Treatment duration will range from a minimum of approximately 2 months to 6 months per subject. A subject may receive a minimum of one dose level or up to a maximum of 5 dose levels, in sequentially increasing dose strengths. Each dose level will last 28 days.

03

Conditions studied

  • Congenital Adrenal Hyperplasia

Keywords

  • ATR-101
  • classic congenital adrenal hyperplasia
  • 21-hydroxylase deficiency
  • CAH
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented historical diagnosis of classic CAH due to 21-hydroxylase deficiency based on: Documented genetic mutation in the CYP21A2 enzyme consistent with a diagnosis of classic CAH, or historical documentation of elevated 17-hydroxyprogesterone
  • Biochemical marker of disease status of 17-hydroxyprogesterone ≥ 4 times the
  • Chronic replacement therapy for at least 6 consecutive months
  • Stable glucocorticoid and mineralocorticoid regimen for at least 1 month

Exclusion criteria

Exclusion Criteria:

  • Non-classic CAH
  • Other causes of adrenal insufficiency
  • Surgery within the previous 3 months prior to screening or planned surgery during study participation
  • History of active cancer requiring medical or surgical therapy within the past 6 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    ATR-101

    Ascending dose levels of ATR-101 beginning with 125 mg by mouth twice per day up to 1000 mg twice per day.

    Drug: ATR-101

Interventions

  • 125-1000 mg twice per week

    Also known as: Nevanimibe hydrochloride

06

What researchers measure

Primary outcomes

  1. Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101

    17-hydroxyprogesterone was measured predose in the morning at the beginning and end of each dose level.

    Time frame: Evaluated at baseline and day 15 of each dose level. Each subject will have up to 5 dose levels.

07

Results

Posted Feb 17, 2021
Limitations and caveats
The small number of subjects analyzed as a result of the rarity of the disease (congenital adrenal hyperplasia).and the stage of the study (phase 2a)

Participant flow

Participant flow — Overall Study
MilestoneATR-101
Started10
Completed9
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101

17-hydroxyprogesterone was measured predose in the morning at the beginning and end of each dose level.

Time frame:
Evaluated at baseline and day 15 of each dose level. Each subject will have up to 5 dose levels.
Reported as:
Count of participants · Participants
Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-101
ParticipantsATR-101
Number of Participants With Reduction of 17-hydroxyprogesterone to </= 2 Times the Upper Limit of Normal at Any Time Following 2 Weeks of Dosing With ATR-1012

Adverse events

Collected over Adverse events were collected from the time the patient signed informed consent until 4 weeks after the last dose of active drug.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATR-1010/10 (0%)1/10 (10%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventATR-101
EnteritisGastrointestinal disorders1/10
Most frequent other events
Showing 10 of 33
Most frequent other events
EventATR-101
NasopharyngitisInfections and infestations4/10
HeadacheNervous system disorders4/10
Abdominal pain upperGastrointestinal disorders3/10
DiarrhoeaGastrointestinal disorders3/10
MigraineNervous system disorders3/10
VomitingGastrointestinal disorders2/10
Nasal congestionRespiratory, thoracic and mediastinal disorders2/10
AcneSkin and subcutaneous tissue disorders2/10
Atrioventricular block first degreeCardiac disorders1/10
DyspepsiaGastrointestinal disorders1/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)ATR-101
Mean30.3 ± 13.76
Sex: Female, Male
Sex: Female, Male(Participants)ATR-101
Female5
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ATR-101
Hispanic or Latino1
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATR-101
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ATR-101
United States10
17-hydroxyprogesterone
17-hydroxyprogesterone(ng/dL)ATR-101
Mean6591.0 ± 5371.80
08

Study locations

6 sites
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
  • The University of Oklahoma - Tulsa Schusterman Center
    Tulsa, Oklahoma 74135, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 10021, United States
09

References and documents

Publications

  • El-Maouche D, Merke DP, Vogiatzi MG, Chang AY, Turcu AF, Joyal EG, Lin VH, Weintraub L, Plaunt MR, Mohideen P, Auchus RJ. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2020 Aug 1;105(8):2771-8. doi: 10.1210/clinem/dgaa381. PubMed 32589738 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Aug 2017, 14 months.

Results were first posted in Feb 2021, 3 years 6 months after primary completion. A results delay was requested in Oct 2019.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2016
First posted
Jun 17, 2016
StartActual
May 18, 2016
Primary completionActual
Aug 17, 2017
CompletionActual
Aug 17, 2017
Results delay requested
Oct 16, 2019
Results first posted
Feb 17, 2021
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02804178
Lead sponsor
Millendo Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2016
Start date
May 18, 2016
Primary completion
Aug 17, 2017
Completion
Aug 17, 2017
Results posted
Feb 17, 2021
Last update
Mar 10, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pd-132301 hydrochloride

Start the discussion